-+ 0.00%
-+ 0.00%
-+ 0.00%

Dyne Therapeutics Q3 2026 net loss widens 79% to $193.55 million

PUBT·11/05/2026 12:39:45
Dyne Therapeutics Q3 2026 net loss widens 79% to $193.55 million
  • Dyne Therapeutics’ third-quarter 2026 net loss widened 79% year over year to $193.55 million.
  • R&D expenses rose 66% year over year to $161.74 million, while general and administrative expenses more than doubled to $35.33 million.
  • Cash, cash equivalents and marketable securities totaled $1.13 billion September 30, sufficient to fund operations into the second quarter of 2028.
  • Z-rostudirsen’s FDA priority review has a January 21, 2027, target action date; a potential US launch remains expected in Q1 2027.
  • Z-basivarsen registrational expansion cohort topline data remain planned for Q1 2027, supporting a potential accelerated-approval application in Q3 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870879) on November 05, 2026, and is solely responsible for the information contained therein.